Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in 2025 slightly exceeded previous expectations, with total revenue of HKD 14.58 billion, a year-on-year increase of 11.5%, and a net profit attributable to shareholders of HKD 980.29 million, up 14.82% year-on-year [7] - The company is expected to continue improving its profit margins, with a projected gross margin of 10.43% in 2026, up from 10.1% in 2025 [7] - The company is positioned as the only publicly listed entity under China Tobacco International, focusing on the export of tobacco products and expanding its global footprint [7] Financial Projections - Total revenue projections for the company are as follows: - 2024: HKD 13.07 billion - 2025: HKD 14.58 billion - 2026: HKD 15.77 billion - 2027: HKD 17.16 billion - 2028: HKD 18.54 billion - The net profit attributable to shareholders is projected to be: - 2024: HKD 853.74 million - 2025: HKD 980.29 million - 2026: HKD 1.10 billion - 2027: HKD 1.34 billion - 2028: HKD 1.56 billion [1][8] - The earnings per share (EPS) forecast is as follows: - 2024: HKD 1.23 - 2025: HKD 1.42 - 2026: HKD 1.59 - 2027: HKD 1.94 - 2028: HKD 2.26 [1][8] Business Segmentation - Revenue from different business segments in 2025 includes: - Tobacco leaf imports: HKD 9.54 billion (up 16% year-on-year) - Tobacco leaf exports: HKD 2.48 billion (up 20% year-on-year) - Cigarette exports: HKD 1.67 billion (up 6% year-on-year) - New tobacco products: HKD 0.06 billion (down 52% year-on-year) - Brazilian operations: HKD 0.83 billion (down 21% year-on-year) [7] - The company plans to optimize its supply chain, which is expected to enhance the gross margin of its cigarette export business [7]
中烟香港：盈利能力提升，加速全球布局-20260310